{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:46:00Z","timestamp":1762623960779},"reference-count":15,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,7]]},"abstract":"<jats:p>Miltefosine is the only orally administrable drug for the treatment of leishmaniasis. But in recent years, a decline in its efficacy points toward the emergence of resistance to this drug. Knowledge of biomarkers for miltefosine resistance may be beneficial for proper selection of treatment regimen. Splenic aspirates were collected and parasites cultured from patients relapsed after initial cure (<jats:italic>N<\/jats:italic> = 15) and successfully treated (<jats:italic>N<\/jats:italic> = 15) with miltefosine. Differential expression of genes in miltefosine-resistant strains was examined by DNA microarray and validated by real-time reverse transcription polymerase chain reaction and Western blotting. Of 669 upregulated genes, the cysteine protease-like protein of calpain family (GenBank: CBZ34784) was found to be significantly overexpressed in resistant parasite strains and only anti-calpain antibodies showed its presence in the sera of relapse patients through Western blotting. Calpain family cysteine protease-like protein can be useful as a potential biomarker of miltefosine unresponsiveness.<\/jats:p>","DOI":"10.4269\/ajtmh.16-0983","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T07:00:39Z","timestamp":1514358039000},"page":"492-496","source":"Crossref","is-referenced-by-count":3,"title":["Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis"],"prefix":"10.4269","volume":"98","author":[{"given":"Puja","family":"Tiwary","sequence":"first","affiliation":[{"name":"Department of Medicine, Infectious Disease Research Laboratory, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Infectious Disease Research Laboratory, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam","family":"Sundar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Infectious Disease Research Laboratory, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000"},{"year":"2005","author":"WHO","key":"b2"},{"key":"b3","series-title":"Ther Clin Risk Manag","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007"},{"key":"b4","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012"},{"key":"b5","series-title":"Trends Parasitol","first-page":"162","article-title":"Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs","volume":"33","author":"Hefnawy","year":"2016"},{"key":"b6","series-title":"Genome Res","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1101\/gr.123430.111","article-title":"Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance","volume":"21","author":"Downing","year":"2011"},{"key":"b7","series-title":"Nucleic Acids Res","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002"},{"key":"b8","series-title":"Trop Med Int Health","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/j.1365-3156.2008.02154.x","article-title":"Diagnostic accuracy of a new Leishmania PCR for clinical visceral leishmaniasis in Nepal and its role in diagnosis of disease","volume":"13","author":"Deborggraeve","year":"2008"},{"key":"b9","series-title":"Methods","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001"},{"key":"b10","series-title":"J Mol Biomark Diagn","first-page":"1000141","article-title":"Cloning, expression and purification of L. donovani specific antigen for serodiagnosis of visceral leishmaniasis","volume":"4","author":"Kumar","year":"2013"},{"key":"b11","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013"},{"key":"b12","series-title":"Am J Trop Med Hyg","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4269\/ajtmh.2011.10-0661","article-title":"Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh","volume":"85","author":"Rahman","year":"2011"},{"key":"b13","series-title":"Clin Pharmacol Ther","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001"},{"key":"b14","series-title":"Mol Biochem Parasitol","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0166-6851(01)00296-1","article-title":"CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei","volume":"116","author":"Hertz-Fowler","year":"2001"},{"key":"b15","series-title":"Parasitology","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S0031182099006435","article-title":"Analysis of the roles of cysteine proteinases of Leishmania mexicana in the host-parasite interaction","volume":"121","author":"Frame","year":"2000"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/98\/2\/article-p492.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/98\/2\/article-p492.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/98\/2\/article-p492.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:10:59Z","timestamp":1722445859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/98\/2\/article-p492.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":15,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.16-0983","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"type":"print","value":"0002-9637"},{"type":"electronic","value":"1476-1645"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}